切换至 "中华医学电子期刊资源库"
高级检索
中华临床医师杂志(电子版)

中华临床医师杂志(电子版) ›› 2022, Vol. 16 ›› Issue (06) : 529 -535. doi: 10.3877/cma.j.issn.1674-0785.2022.06.012

临床研究

血清miR-146b-3p、miR-15b-5p、miR-16-5p在良恶性肺结节鉴别诊断、预后评估中的价值
曹炜1, 赵大海2,†(), 赵旭东1   
  1. 1. 230601　安徽合肥，安徽医科大学第二附属医院胸外科
    2. 230601　安徽合肥，安徽医科大学第二附属医院呼吸与危重医学科
  • 收稿日期:2021-09-15 出版日期:2022-06-15
  • 通信作者: 赵大海
  • 基金资助:
    合肥市自然科学基金项目(2021037)

Value of serum miR-146b-3p, miR-15b-5p, and miR-16-5p in differential diagnosis and prognosis evaluation of benign and malignant pulmonary nodules

Wei Cao1, Dahai Zhao2,†(), Xudong Zhao1   

  1. 1. Department of Thoracic Surgery, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
    2. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
  • Received:2021-09-15 Published:2022-06-15
  • Corresponding author: Dahai Zhao
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

曹炜, 赵大海, 赵旭东. 血清miR-146b-3p、miR-15b-5p、miR-16-5p在良恶性肺结节鉴别诊断、预后评估中的价值[J]. 中华临床医师杂志(电子版), 2022, 16(06): 529-535.

Wei Cao, Dahai Zhao, Xudong Zhao. Value of serum miR-146b-3p, miR-15b-5p, and miR-16-5p in differential diagnosis and prognosis evaluation of benign and malignant pulmonary nodules[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(06): 529-535.

目的

探究微小RNA（miR）-146b-3p、miR-15b-5p、miR-16-5p在良恶性肺结节鉴别诊断以及预后评估中价值。

方法

前瞻性选择2018年6月至2020年6月期间安徽医科大学第二附属医院收治139例肺结节患者作为研究对象，行病理检查或者穿刺活检后确定患者病灶良恶性，其中良性组75例，恶性组64例。2组患者均测定血清miR-146b-3p、miR-15b-5p、miR-16-5p。分析上述指标在患者良恶性结节诊断上价值，恶性组患者血清miR-146b-3p、miR-15b-5p、miR-16-5p与患者病理特征之间关系。随访评估恶性组患者预后，分析血清miR-146b-3p、miR-15b-5p、miR-16-5p对预后预测价值。

结果

良性组患者血清miR-146b-3p、miR-15b-5p显著低于恶性组（P＜0.05），miR-16-5p显著高于恶性组（P＜0.05）。受试者工作特征（ROC）曲线显示，血清miR-146b-3p、miR-15b-5p、miR-16-5p及各种指标联合对于结节良恶性诊断曲线下面积（AUC）分别为0.803、0.786、0.889、0.962。血清miR-146b-3p、miR-15b-5p、miR-16-5p与分化程度、淋巴结转移、临床分期类型有关（P＜0.05）；Spearman相关性分析显示，血清miR-146b-3p、miR-15b-5p均与分化程度呈显著的负相关，且均有统计学意义（r=-0.534，-0.468；P＜0.05），均与淋巴结转移呈显著的正相关，且均有统计学意义（r=0.582，0.608；P＜0.05），均与临床分期类型呈显著的正相关（r=0.486，0.519；P＜0.05）；miR-16-5p与分化程度、淋巴结转移、临床分期分别呈显著的正相关、负相关、负相关（r=0.412，-0.563，-0.657；P＜0.05），且均有统计学意义。预后不良恶性组患者血清miR-146b-3p、miR-15b-5p显著高于恶性组，miR-16-5p显著高于预后良好患者，且上述差异均有统计学意义（P＜0.05）。ROC曲线显示，血清miR-146b-3p、miR-15b-5p、miR-16-5p及各指标联合对于恶性结节患者预后预测AUC分别为0.799、0.772、0.554、0.837。

结论

血清miR-146b-3p、miR-15b-5p、miR-16-5p与肺结节良恶性、恶性结节临床特征以及恶性结节患者预后关系密切，三种血清指标联合用于肺结节良恶性鉴别诊断以及预后预测价值优异。

关键词: 血清微RNA, 肺结节, 良恶性鉴别诊断, 预后评估
Objective

To evaluate the value of microRNA (miR)-146b-3p, miR-15b-5p, and miR-16-5p in the differential diagnosis and prognosis evaluation of benign and malignant pulmonary nodules.

Methods

Totally 139 patients with pulmonary nodules admitted to our hospital were selected as the research subjects between June 2018 and June 2020. Based on postoperative pathological results or biopsy results, the patients were divided into a benign group (n=75) and a malignant group (n=64). Serum miR-146b-3p, miR-15b-5p, and miR-16-5p in the two groups were measured, and their diagnostic value in benign and malignant nodules was analyzed. The relationship between serum miR-146b-3p, miR-15b-5p, or miR-16-5p and pathological characteristics in the malignant group was analyzed. The prognosis of patients in the malignant group was evaluated, and the prognostic value of serum miR-146b-3p, miR-15b-5p, and miR-16-5p was analyzed.

Results

Serum miR-146b-3p and miR-15b-5p in the benign group were significantly lower than those in the malignant group (P＜0.05), and miR-16-5p was significantly higher than that in the malignant group (P＜0.05). Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) values of serum miR-146b-3p, miR-15b-5p, and miR-16-5p, alone and in combination, to diagnose benign and malignant nodules were 0.803, 0.786, 0.889, and 0.962, respectively. Serum miR-146b-3p, miR-15b-5p, and miR-16-5p were related to differentiation degree, lymph node metastasis, and clinical stage (P＜0.05). Spearman correlation analysis showed that both serum miR-146b-3p and miR-15b-5p were significantly negatively correlated with differentiation degree (r=-0.534 and -0.468, respectively, P＜0.05), and significantly positively correlated with lymph node metastasis (r=0.582 and 0.608, respectively, P＜0.05) and clinical stage (r=0.486 and 0.519, respectively, P＜0.05). Serum miR-16-5p was significantly positively correlated with differentiation degree, and significantly negatively correlated with lymph node metastasis and clinical stage (r=0.412, -0.563, and -0.657, respectively, P＜0.05). In the malignant group, serum miR-146b-3p and miR-15b-5p in patients with a poor prognosis were significantly higher than those in patients with a good prognosis, and miR-16-5p was significantly lower in patients with a poor prognosis than that in patients with a good prognosis (P＜0.05). ROC curve analysis showed that the AUC values of serum miR-146b-3p, miR-15b-5p, miR-16-5p, alone and in combination, for evaluating the prognosis of patients with malignant nodules were 0.799, 0.772, 0.774, and 0.881, respectively.

Conclusion

Serum miR-146b-3p, miR-15b-5p, and miR-16-5p are closely related to clinical characteristics of benign and malignant pulmonary nodules and the prognosis of patients with malignant nodules. Combination of the three is of high value in the differential diagnosis of benign and malignant pulmonary nodules.

Key words: Serum microRNA, Pulmonary nodule, Differential diagnosis of benign and malignant, Prognosis evaluation
表1 比较良恶性结节血清miRNA水平（
xˉ
±s）
组别 例数 miR-146b-3p miR-15b-5p miR-16-5p
良性组 75 0.64±0.21 7.64±1.44 26.25±3.37
恶性组 64 0.96±0.32 10.07±2.95 19.27±5.24.
t值 7.242 6.954 9.470
P值 ＜0.001 ＜0.001 ＜0.001
表2 血清miRNA水平对于结节良恶性诊断价值分析
指标 截断值 AUC 敏感度 特异度 95%CI P值
miR-146b-3p 0.84 0.803 64.1 86.7 0.727~0.879 ＜0.001
miR-15b-5p 9.15 0.786 56.3 96.0 0.704~0.867 ＜0.001
miR-16-5p 22.43 0.889 79.7 90.7 0.831~0.947 ＜0.001
各指标联合 - 0.962 87.5 93.3 0.933~0.991 ＜0.001
图1 血清miRNA水平对于结节良恶性诊断价值分析
表3 比较恶性组不同病理资料患者血清miRNA水平（
xˉ
±s）
病理资料 例数 miR-146b-3p t值 P值 miR-15b-5p t值 P值 miR-16-5p t值 P值
年龄（岁） 0.256 0.799 0.231 0.818 0.322 0.748
＜60 24 0.95±0.29 9.97±2.53 19.03±4.21
≥60 40 0.97±0.31 10.13±2.76 19.41±4.76
性别 0.407 0.686 0.191 0.849 1.666 0.101
男 39 0.97±0.28 10.12±2.74 18.53±4.26
女 25 0.94±0.30 9.99±2.51 20.42±4.68
吸烟史 1.054 0.296 1.036 0.304 0.410 0.683
是 35 0.99±0.26 9.75±2.66 19.08±4.22
否 29 0.92±0.27 10.46±2.81 19.50±3.91
组织学类型 0.497 0.621 0.843 0.402 1.344 0.184
腺癌 43 0.95±0.22 9.86±2.75 19.69±3.25
鳞状细胞癌 21 0.98±0.24 10.50±3.05 18.41±4.18
病灶尺寸（cm） 0.315 0.754 0.156 0.877 1.032 0.306
＜3 23 0.97±0.25 10.14±2.66 18.56±3.27
≥3 41 0.95±0.24 10.03±2.74 19.67±4.53
分化程度 22.889 ＜0.001 17.966 ＜0.001 32.498 ＜0.001
低分化 20 1.25±0.31 12.34±3.15 14.81±3.91
中分化 26 0.89±0.24 10.07±2.09 19.77±2.84
高分化 18 0.74±0.19 7.55±1.79 23.50±2.36
淋巴结转移 4.083 ＜0.001 5.054 ＜0.001 4.122 ＜0.001
是 28 1.09±0.24 11.97±2.51 17.50±4.19
否 36 0.86±0.21 8.59±2.76 20.65±3.66
临床分期类型 2.368 0.021 5.242 ＜0.001 4.632 ＜0.001
Ⅰ+Ⅱ 36 0.89±0.22 8.56±2.15 21.32±3.51
Ⅲ+Ⅳ 28 1.05±0.32 12.01±3.11 16.63±4.19
表4 比较不同预后恶性组患者血清miRNA水平（
xˉ±s
）
组别 例数 miR-146b-3p miR-15b-5p miR-16-5p
预后不良组 23 1.15±0.29 13.42±4.52 15.55±4.56
预后良好组 41 0.85±0.31 8.19±2.56 21.36±4.40
t值 4.575 4.482 5.003
P值 ＜0.001 ＜0.001 ＜0.001
表5 分析血清miRNA水平对于恶性结节患者预后预测价值
指标 截断值 AUC 敏感度 特异度 95% CI P值
miR-146b-3p 0.97 0.799 78.3 80.5 0.686~0.912 ＜0.001
miR-15b-5p 9.54 0.772 78.3 70.7 0.638~0.906 ＜0.001
miR-16-5p 17.66 0.554 52.2 63.4 0.424~0.678 0.480
各指标联合 - 0.837 60.9. 97.6 0.727~0.947 ＜0.001
图2 血清miRNA水平对于恶性结节患者预后预测价值分析ROC曲线
1
Godoy MCB, EGLCOdisio, Truong MT, et al. Pulmonary nodule management in lung cancer screening: a pictorial review of lung-RADS version 1.0 [J]. Radiol Clin North Am, 2018, 56(3): 353-363.
2
Gong L, Jiang S, Yang Z, et al. Automated pulmonary nodule detection in CT images using 3D deep squeeze-and-excitation networks [J]. Int J Comput Assist Radiol Surg, 2019, 14(11): 1969-1979.
3
Zhang S, Sun F, Wang N, et al. Computer-aided diagnosis (CAD) of pulmonary nodule of thoracic CT image using transfer learning [J]. J Digit Imaging, 2019, 32(6): 995-1007.
4
钟华, 李安琪, 康江河, 等. ≤20 mm孤立性肺结节良恶性预测模型的建立与验证 [J]. 中华放射学杂志, 2021, 55(7): 745-750.
5
Xi KX, Zhang XW, Yu XY, et al. The role of plasma miRNAs in the diagnosis of pulmonary nodules [J]. J Thorac Dis, 2018, 10(7): 4032-4041.
6
史佳民, 刘娣, 范理宏. 七种微小RNA在良恶性肺结节鉴别诊断中的价值 [J]. 同济大学学报(医学版), 2019, 40(2): 169-173.
7
中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版) [J]. 中华肿瘤杂志, 2018, 40(12): 935-964.
8
周舒畅, 王玉锦, 黄璐, 等. 扩散峰度成像与扩散加权成像在难鉴别孤立性肺结节良恶性判定价值的比较研究 [J]. 中华放射学杂志, 2019, 53(3): 200-204.
9
崔胜金, 曹朝鹏, 郭伟权, 等. 非小细胞肺癌早期诊断的潜在生物标志物:血浆miRNA-23 a和miRNA-451 [J]. 南方医科大学学报, 2019, 39(6): 705-711.
10
Wang B, Duan R, Li ZB, et al. Circ-RPL15/miR-146 b-3 p/VEGFA feedback loop is responsible for triggering proliferation and migration in glioma [J]. Eur Rev Med Pharmacol Sci, 2020, 24(11): 6204-6210.
11
张晓楠, 冯浩, 白雪, 等. miR-15b-5p靶向CDK4抑制脉络膜黑色素瘤细胞增殖 [J]. 中国医科大学学报, 2019, 48(3): 230-235.
12
Ahmad S, Ahmed MM, Hasan PMZ, et al. Identification and validation of potential miRNAs, as biomarkers for sepsis and associated lung injury: a network-based approach [J]. Genes (Basel), 2020, 11(11): 1327-1343.
13
史佳民, 刘娣, 范理宏. 七种微小RNA在良恶性肺结节鉴别诊断中的价值 [J]. 同济大学学报(医学版), 2019, 40(2): 169-173.
14
Fan L, Sha J, Teng J, et al. Evaluation of serum paired MicroRNA ratios for differential diagnosis of non-small cell lung cancer and benign pulmonary diseases [J]. Mol Diagn Ther, 2018, 22(4): 493-502.
15
Xi KX, Zhang XW, Yu XY, et al. The role of plasma miRNAs in the diagnosis of pulmonary nodules [J]. J Thorac Dis, 2018, 10(7): 4032-4041.
16
Wang Y, Zheng F, Wang Z, et al. Circular RNA circ-SLC7A6 acts as a tumor suppressor in non-small cell lung cancer through abundantly sponging miR-21 [J]. Cell Cycle, 2020, 19(17): 2235-2246.
17
He Y, Ren S, Wang Y, et al. Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules [J]. J Thorac Dis, 2018, 10(8): 5080-5085.
18
吐尔逊江·艾力, 曹国磊, 陈慧芳, 等. miR-9和MMP-14在非小细胞肺癌中的表达及临床意义 [J]. 临床肿瘤学杂志, 2021, 26(6): 554-558.
19
杨寿艳, 邓彬兵, 孟雄, 等. 肺癌患者血清miRNA-4534水平和病理分期与预后的关系 [J]. 分子诊断与治疗杂志, 2020, 12(10): 1319-1322, 1327.
20
Xu J, Zhang J, Shan F, et al. SSTR5-AS1 functions as a ceRNA to regulate CA2 by sponging miR-15b-5p for the development and prognosis of HBV-related hepatocellular carcinoma [J]. Mol Med Rep, 2019, 20(6): 5021-5031.
21
Krell A, Wolter M, Stojcheva N, et al. MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy [J]. Neuropathol Appl Neurobiol, 2019, 45(5): 441-458.
22
Li Y, Zhang H, Dong Y, et al. MiR-146 b-5 p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer [J]. J Cancer, 2017, 8(9): 1704-1716.
[1] 王友芳, 李兴超, 朱晓松, 刘清敏, 张建国, 杨淑红, 相然, 张蒙蒙, 车峰远. 预后营养指数对急性颅内动脉粥样硬化性大血管闭塞患者预后评估价值分析[J]. 中华危重症医学杂志(电子版), 2023, 16(03): 193-197.
[2] 陈经欣, 李梅, 陈洁雅. 肺结节胸腔镜术后肺部感染危险因素分析[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(04): 238-243.
[3] 任茂玲, 孙晓容, 何晓丽. CT引导下微波消融术在肺部结节治疗中的应用及术后并发症的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(05): 718-720.
[4] 蒋丽, 王晓慧, 李维益, 苟双芸, 丁敏, 杨丽. 创新智能健康教育与随访管理对肺结节患者焦虑的影响随机对照研究[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 485-489.
[5] 李华娟, 唐英俊, 王赛妮, 徐旺, 林玲, 李羲, 黄华萍. 肺结节临床与CT影像学特征分析及良恶性预测模型构建[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 318-323.
[6] 王洪武, 方碧霞. 基于人工智能探讨多发性肺结节的诊治策略[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 301-305.
[7] 陈冀, 邓才霞, 张厚丽, 祝冰晶, 刘攀, 何建, 唐春兰, 周向东, 罗虎. 高危肺结节患者认知及焦虑状况调查分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 164-168.
[8] 郑晴晴, 王剑, 阳韬. 外泌体miRNA对肺结节的诊断进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 293-295.
[9] 潘玥, 夏婷, 王燕, 顾娟. 肺结节患者生活质量影响因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 272-274.
[10] 胥凯凯, 李铁铮, 刘春全, 崔永. 肺小结节精准定位日间手术流程及临床疗效分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 230-232.
[11] 国宇, 周全红, 孟凡祺. 双源CT联合循环肿瘤细胞对独立性肺结节的预测意义[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 61-63.
[12] 汪玲玲, 申潇竹, 贾嵘, 包勤文. CRP/AIb、NLR及CD64%对老年肺部感染预后的意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 859-862.
[13] 丁薇, 王保兰, 李朋玲. 硫氧还蛋白还原酶联合肺癌标志物对肺结节良恶性的诊断意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(05): 685-687.
[14] 赵志鹏, 马永富, 冯长江, 张猛, 刘阳. 以肺亚段为解剖单位的精准肺外科手术策略的初步报道[J]. 中华腔镜外科杂志(电子版), 2023, 16(02): 85-90.
[15] 张青岛, 王华龙. MRI表观弥散系数及体素内不相干运动参数对中老年患者肺结节性质的鉴别诊断价值[J]. 中华老年病研究电子杂志, 2023, 10(01): 26-29.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号